SCHEMBL6776012

SCHEMBL6776012

COC(=O)c1ccccc1OCC(C)Cl

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.50
HSP90AA1 P07900 2/20 0.49
MAPT P10636 2/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ALDH1A1 P00352 3/20 0.48
TSHR P16473 2/20 0.48
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.45
SLC6A4 P31645 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385218 0.87 ALDH1A1 (0.54) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL21505718 0.84 SLC6A3 (0.50) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL6042447 0.84 SLC6A3 (0.50) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL16836610 0.83 SLC6A3 (0.51) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL28136228 0.82 SLC6A3 (0.57) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL10842173 0.79 ADRB2 (0.68) ALDH1A1TSHRCYP1A2CYP2C9SMN1; SMN2
SCHEMBL30553984 0.78 HCRTR1 (0.65) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL1989129 0.78 HCRTR1 (0.65) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL4385291 0.78 SLC6A3 (0.57) SLC6A3HSP90AA1MAPTHTTNPSR1
SCHEMBL385728 0.78 HTT (0.70) SLC6A3HSP90AA1MAPTHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1183251-B1 INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS ALMIRALL PRODESFARMA SA (ES) 2004-02-11 EP disclosed
US-6683096-B2 Indolylpiperidine derivatives as antihistaminic and antiallergic agents ALMIRALL PRODESFARMA, S.A. (ES) 2004-01-27 US disclosed
US-20020147344-A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents ALMIRALL PRODESFARMA, S.A. (ES) 2002-10-10 US disclosed
EP-1183251-A1 INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS Almirall Prodesfarma, S.A. (ES) 2002-03-06 EP disclosed
WO-2000075130-A1 INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS ALMIRALL PRODESFARMA, S.A. (ES) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147344-A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents HRH2, HRH1, HRH4 SLC6A3 1220/4885HSP90AA1 2240/4885MAPT 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.